Latest News - Biogen

Top Corporates Hub

Biogen

BIIB | NASDAQ | United States
865
-305
Rank
$32.85B
Market Cap
$9.67B
-$ 0.16B
-1.63%
Revenue
$1.90B
+$ 0.61B
+47.29%
Earnings
7.6K
+0K
+0.46%
Employees
Why Biogen (BIIB) Could Beat Earnings Estimates Again

07.04.2026 16:10

Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Read More

Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform

07.04.2026 10:00

BOSTON, April 07, 2026--Alloy Therapeutics Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced a collaboration and license agreement with Biogen Inc. for the use of Alloy’s novel and proprietary AntiClastic™ ASO Platform. Through this collaboration, Biogen will apply the platform to advance antisense therapeutics against multiple undisclosed targets. Alloy will receive an upfront payment and is eligible

Read More

Biogen Taps Alloy Platform To Push Antisense Drug Pipeline Forward

07.04.2026 08:54

Biogen partners with Alloy Therapeutics to advance antisense therapies using RNA-targeting technology, expanding its pipeline.

Read More

1 Mid-Cap Stock with Promising Prospects and 2 We Brush Off

07.04.2026 07:17

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.

Read More

Biogen Teams Up With Alloy To Develop Next-Gen RNA Drugs, Targets Hard-To-Reach Diseases With Advanced Antisense Technology

07.04.2026 06:05

Alloy Therapeutics Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced a collaboration and license agreement with Biogen Inc.

Read More

Why Biogen Stock Sank While the Market Soared on Thursday

01.04.2026 00:19

It's reaching into its coffers for a $5.6 billion acquisition.

Read More

Top Midday Stories: McCormick to Combine With Unilever's Foods Business; Eli Lilly to Acquire Centessa for Up to $7.8 Billion

31.03.2026 15:35

All three major US stock indexes were up, while the price of oil was down in late-morning trading Tu

Read More

Nvidia invests $2B in Marvell, Eli Lilly to buy drugmaker Centessa

31.03.2026 15:27

Yahoo Finance Senior Reporter Brooke DiPalma takes a closer look at some of Tuesday morning's trending tickers and stories, including some of the latest deals and investments.Nvidia (NVDA) is investing $2 billion in Marvell (MRVL).Biogen (BIIB) is buying Apellis Pharmaceuticals (APLS) for $5.6 billion.Eli Lilly (LLY) is set to buy sleep-drug maker Centessa (CNTA) for up to $7.8 billion.

Read More

Biogen Details $5.6B Apellis Deal, Sees Mid-to-High-Teens Growth and EPS Accretion by 2027

31.03.2026 14:10

Biogen (NASDAQ:BIIB) executives outlined their rationale and financial expectations for a proposed acquisition of Apellis during a business update call, positioning the deal as a way to add near-term commercial growth while deepening the company’s push into immunology, rare disease, and nephrology.

Read More

Why This Pharma Stock More Than Doubled Today

31.03.2026 13:41

A small biopharmaceutical firm was getting a big boost Tuesday after Biogen agreed to buy it for $5.6 billion.

Read More

Sector Update: Health Care Stocks Advance Premarket Tuesday

31.03.2026 13:18

Health care stocks were advancing premarket Tuesday, with the State Street Health Care Select Sector

Read More

Wall Street Weighs Signs Trump May End Iran War Even With Strait Shut, Driving Premarket Gains for Equity Futures

31.03.2026 13:08

US equity futures were up ahead of Tuesday's opening bell amid signs of President Donald Trump's wil

Read More

Biogen Snaps Up Apellis Pharma For $5.6 Billion, But Biogen Dives As Apellis Soars

31.03.2026 13:02

Biogen struck a deal Tuesday to buy Apellis Pharmaceuticals for $5.6 billion. The buyout adds two approved drugs to Biogen's pipeline.

Read More

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday as De-Escalation Hopes Lift Risk Sentiment

31.03.2026 12:51

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 1% and the actively traded

Read More

Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion in Cash Plus Potential Additional Payments

31.03.2026 11:47

Biogen (BIIB) has agreed to acquire Apellis Pharmaceuticals (APLS) for about $5.6 billion in cash pl

Read More

Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion

31.03.2026 11:44

Biogen agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion, expanding its portfolio in immunology and rare-disease medicines.

Read More

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

31.03.2026 10:59

Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE® FDA-approved in geographic atrophy, an immune-mediated retinal diseaseBringing together Biogen and Apellis’ commercialization capabilities will maximize the potential of both EMPAVELI® and SYFOVRE®, while Apellis’ talent and expertise will accelerate Biogen’s entry into nephrology and augment launch readiness fo

Read More

Biogen Lands Two Fast-Growing Drugs In Blockbuster Apellis Deal

31.03.2026 10:16

Apellis surges after Biogen's $5.6 billion buyout at $41 per share, adding complement therapies and boosting long-term EPS outlook.

Read More

These Stocks Are Today’s Movers: Microsoft, McCormick, Unilever, Nike, and More

31.03.2026 10:16

Microsoft gains after announcing an investment of more than $1 billion in cloud and AI infrastructure in Thailand.

Read More

Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

31.03.2026 09:57

US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave Life, Perimeter Solutions, Praxis Precision, and Century Aluminum.

Read More